Amylin Pharmaceuticals

A–Z list of Amylin Pharmaceuticals’ products

Byetta (exenatide)
Indication: Type 2 diabetes management (adjunct to oral antidiabetic agents)
Dose: 5–10 micrograms subcutaneous injection, twice daily before meals

Bydureon (exenatide extended-release)
Indication: Type 2 diabetes management
Dose: 2 mg subcutaneous injection, once weekly

Symlin (pramlintide acetate)
Indication: Adjunct therapy to insulin in type 1 and type 2 diabetes not achieving glycemic control
Dose: 15–60 micrograms subcutaneous injection before meals, titrated by response

Metreleptin (recombinant leptin, pipeline)
Indication: Metabolic disorders associated with lipodystrophy
Status: Development for diabetes and hypertriglyceridemia; explored for weight and metabolic control

AC165198 (pipeline peptide hybrid)
Indication: Investigational therapy for diabetes
Status: Early-stage development, dosing not publicly established